RE:RE:RE:If you asked for a show of hands...& there it is in a nut shell
"Unfortunatly BTI just has concepts"
as it has no human data and xB3 is several years behind Denali. jd has been worried about gene-therapy approaches too. Midatech is in the clinic with its lead drug with human data in hand. Revenue is potentially much closer. How many years until xB3 is in clinic and at what price? How many years untl it is earning revenue instead of another year of dilution?
If none of the companies that have investigated xB3 is willing to step up and offer a better deal to BTI shareholders than the Midatech deal right now what does that say? Now is their chance as BTI is pinned to the mat by the worst biotech market in history, its debt obligations, and its need to fund the future, etc"
the paln to move forward is "vote no" we need another company to step up or its a big fat YES imo.
Whats the other plan again, just 'vote no"- how painful would that look & be - maybe we should get some big rigs & start honking fricking horns in fornt of head office ,brillant,gezzzzzzzz